This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Apr;51(4):549-53.

doi: 10.1053/j.ajkd.2008.01.007.

Approaching the end of the homocysteine hype?

Gere Sunder-Plassmann¹, Wolfgang C Winkelmayer, Manuela Födinger

Affiliations

PMID: 18371530
DOI: 10.1053/j.ajkd.2008.01.007

Comment

Approaching the end of the homocysteine hype?

Gere Sunder-Plassmann et al. Am J Kidney Dis. 2008 Apr.

. 2008 Apr;51(4):549-53.

doi: 10.1053/j.ajkd.2008.01.007.

Authors

Gere Sunder-Plassmann¹, Wolfgang C Winkelmayer, Manuela Födinger

Affiliation

¹ Medical University Vienna, Vienna, Austria. gere.sunder-plassmann@meduniwien.ac.at

PMID: 18371530
DOI: 10.1053/j.ajkd.2008.01.007

No abstract available

PubMed Disclaimer

Comment on

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Jamison RL, et al. JAMA. 2007 Sep 12;298(10):1163-70. doi: 10.1001/jama.298.10.1163. JAMA. 2007. PMID: 17848650 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science